Summary
Thymidine Kinase 2 deficiency (TK2d, also known as mitochondrial DNA depletion syndrome 2 or mitochondrial DNA depletion syndrome, myopathic form) is a rare genetic mitochondrial disorder that primarily affects muscles. People with this disorder often have progressive muscle weakness and challenges with movement, breathing, and daily activities. TK2d can begin in infancy, childhood, or later in life. The severity and progression of the disorder can vary depending on the subtype.
Description
TK2d is a primary mitochondrial myopathy, meaning that it is a muscle disease caused by a problem in the mitochondria, the energy generators of cells.
TK2d is caused by variations in the TK2 gene. Variations lead to less activity of an enzyme called thymidine kinase 2 (TK2). TK2 normally helps maintain mitochondrial DNA (mtDNA) —the genetic material inside mitochondria responsible for producing energy in cells. When TK2 does not function correctly, muscle cells have less mtDNA, and become weak.
Three main subtypes of TK2d exist:
Early-onset TK2d
Begins before age 1 to 4 years; symptoms progress rapidly and can be life-threatening within 1-2 years.
Childhood-onset TK2d
Begins between ages 1 and 12; disease progresses more slowly, and many affected individuals live for more than a decade after symptoms start.
Late-onset TK2d
Begins after age 12; progression is slower, and individuals may live 20+ years after onset.
Signs and Symptoms
- Progressive muscle weakness, affecting arms and leg, face, and muscles used for breathing and swallowing.
- Difficulty swallowing and speaking, from weakness of throat and facial muscles.
- Droopy eyelids (ptosis) and eye movement problems, like progressive external ophthalmoplegia.
- Respiratory difficulties: Weakness in breathing muscles can require ventilator support.
- Loss of motor skills: Including walking and other daily activities.
- In severe cases, some individuals may experience seizures, hearing loss, or enlarged liver.
Causes
- Genetic variations: Changes in the TK2 gene reduce the activity of thymidine kinase 2 (TK2) enzyme. This is usually inherited in an autosomal recessive pattern, meaning both parents must pass on a faulty gene for a child to be affected. Carriers (one faulty gene) typically do not show symptoms.
- Reduced function of the TK2 enzyme leads to decreased mitochondrial DNA in muscle cells, impairing energy production and leading to muscle weakness.
Laboratory Investigations
Genetic testing
Identifies variations in the TK2 gene.
Muscle biopsy or blood tests
Measures levels of mitochondrial DNA, showing depletion.
Clinical evaluations
Assess muscle strength, breathing function, swallowing, and eye movement.
Imaging and respiratory tests
May be used to evaluate muscle and lung health.
Treatment and Therapies
- Supportive care: Symptom management by a multidisciplinary team including neurologists, pulmonologists, and therapists.
- Respiratory support: May require use of mechanical ventilation over time.
- Physical, occupational, and speech therapy: Help maintain function and quality of life.
- Investigational therapies: Nucleoside supplementation (deoxythymidine and deoxycytidine) is being studied and may improve mitochondrial function. These treatments are currently available only in clinical trials or compassionate use programs.
- Ongoing monitoring: Regular medical follow-up to manage symptoms and complications.
Outlook
- This is an extremely rare disorder. However, it appears that prognosis is variable and depends on age of onset and severity of symptoms.
- When symptoms are identified early, muscle weakness generally worsens rapidly. Difficulties with movement and breathing can shorten the lifespan.
- When symptoms are identified late, muscle weakness generally worsens slowly, with those affected living for decades after symptoms appear.
- Often, people with TK2d require ongoing medical care, therapy, assistive devices, and family support.
Research into new treatments offers hope for improved outcomes.
Resources
- United Mitochondrial Disease Foundation (opens in a new tab)umdf.org
- The Jeremiah Gracen TK2d Foundation (opens in a new tab)tk2dfoundation.com
The Jeremiah Gracen TK2d Foundation is committed to spreading hope for those affected by TK2d by educating, raising awareness, and being a liaison for support services.
- MitoAction (opens in a new tab)mitoaction.org
- Muscular Dystrophy Association (MDA) (opens in a new tab)mda.org
MDA provides access to support and programs that empower the lives of people living with neuromuscular diseases through 150+ multi-disciplinary MDA Care Centers, community education programs, camp and recreation, gene therapy support, advocacy opportunities, and more.
- TK2d Disease Education Brochure — Co-Created with UMDF, MitoAction, Jeremiah Gracen TK2d Foundation, MDA, and MMS (opens in a new tab)childneurologyfoundation.org
This brochure introduces Thymidine Kinase 2 deficiency (TK2d), a rare genetic mitochondrial disease that leads to progressive muscle weakness affecting movement, breathing, and eating. It provides clear information on symptoms, diagnosis, care strategies, and support resources available through healthcare providers and patient organizations. A Spanish version of the brochure is also included for accessibility.
The links and resources included in this section are solicited directly from the community by the Child Neurology Foundation through a formal submission process. CNF reserves the right to remove entities at any time if information is deemed inappropriate or inconsistent with the mission, vision, and values of CNF. The authors listed on this page have not endorsed the resources or links provided in this section.
Research
Currently, there are no listings for “TK2d” in ClinicalTrials.gov. Check back often and talk with your healthcare provider to identify upcoming trials.
If you have an interest in searching for any future trials that may be starting:
- Go to the Home page of ClinicalTrials.gov
- In the “Condition or disease” field, type “Thymidine Kinase 2 deficiency (TK2d)”. A drop-down list will appear if this disorder is included.
- You can narrow the search with the “Other terms”, “Intervention/Treatment”, and “Location” fields.
- Under “Study Status”, click on “Recruiting and not yet recruiting studies”.
- Click on “More Filters”, “Age”, “Child (birth – 17)”.
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. This is a resource provided by the U.S. National Library of Medicine (NLM), which is an institute within the National Institutes of Health (NIH). Listing a study does not mean it has been evaluated by the U.S. Federal Government. Please read the NLM disclaimer for details.
Before participating in a study, you are encouraged to talk to your health care provider and learn about the risks and potential benefits.
Find Clinical Trials For Thymidine Kinase 2 deficiency (TK2d)
Family Stories
The United Mitochondrial Disease Foundation shares touching videos that celebrate the strength and stories of individuals with TK2d and their families.
The information in the CNF Child Neurology Disorder Directory is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. Content provided is for informational purposes only. CNF is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health related diagnosis or treatment options.
References
- National Organization for Rare Disorders (NORD). Thymidine Kinase 2 Deficiency. 2025.
- Garone C, et al. “Late-onset thymidine kinase 2 deficiency: a review of 18 cases.” Orphanet Journal of Rare Diseases. 2019.
- MedlinePlus Genetics. TK2-related mitochondrial DNA depletion syndrome, myopathic form. U.S. National Library of Medicine. 2009.
- Lopez-Gomez C, Sanchez-Quintero MJ, Lee EJ, Kleiner G, Tadesse S, Xie J, Akman HO, Gao G, Hirano M. Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency. Ann Neurol. 2021 Oct;90(4):640-652. doi: 10.1002/ana.26185.
- Nevo Y, Soffer D, Kutai M, Zelnik N, Saada A, Jossiphov J, Messer G, Shaag A, Shahar E, Harel S, Elpeleg O. Clinical characteristics and muscle pathology in myopathic mitochondrial DNA depletion. J Child Neurol. 2002 Jul;17(7):499-504.
- Wang J, El-Hattab AW, Wong LJC. TK2-Related Mitochondrial DNA Maintenance Defect, Myopathic Form. 2012 Dec 6 [updated 2018 Jul 26]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
- UMDF (United Mitochondrial Disease Foundation). TK2d Overview. 2025.
This overview is for general information and is not a substitute for advice from your child's care team.
← Back to the Disorder Directory